KRAS and neoplasm: Although the structure has not been reported, BI-1701963 was selected as a clinical-stage inhibitor of the SOS1:KRAS PPI, and has displayed tumor regressions in several tumor models in mice when dosed in combination with a KRASG12C inhibitor.